- Category: Experimental HIV Drugs
- Published on Monday, 10 March 2014 00:00
- Written by Gregory Fowler
A NRTI-sparing first-line antiretroviral regimen of raltegravir (Isentress) plus ritonavir-boosted darunavir (Prezista) worked as well as standard therapy containing tenofovir/emtricitabine (the drugs in Truvada), according to results from the NEAT 001 trial presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) last week in Boston.
[Francois Raffi, CROI press conference, March 5, 2014]
F Raffi, AG Babiker, L Richert, et al. First-Line RAL + DRV/r Is Non-Inferior To TDF/FTC + DRV/r: The NEAT001/ANRS143 Randomised Trial. 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014). Boston, March 3-6. Abstract 84LB.